Serina Therapeutics, Inc. (SER) Stock

Serina Therapeutics, Inc. (SER) is a Healthcare stock trading at $2.86 (as of 2026-08-21), with a market capitalization of $72.65M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Serina Therapeutics, Inc. is a biotechnology company focused on drug development for neurological disorders, pain, and infectious diseases. Its pipeline includes SER 252, SER 227, SER 214, and SER 228, and it applies POZ technology in lipid nanoparticle–delivered RNA vaccines.

Understand Serina Therapeutics, Inc.: how it makes money

Serina Therapeutics develops biotechnology drugs and related delivery technology for neurological diseases and pain, with its lead program SER 252 for Parkinson's disease, and additional candidates including SER 227 (long-acting pain relief), SER 214 (Parkinson's disease), and SER 228 (epilepsy), plus POZ technology in lipid nanoparticle delivered RNA vaccines for infectious diseases.

Because Serina is primarily a drug development company with multiple investigational candidates, its profit potential is structurally driven by clinical and regulatory progress in its pipeline (and any resulting partnering or commercialization), rather than near-term recurring sales from already marketed products.

Business quality (Weak): The input provides company and pipeline facts, but no official reportable segment breakdown or operational KPI labels, so there is not enough information to quantify performance drivers from the provided dataset.

Bull case

Focused pipeline in neurological diseases and pain: The company is developing multiple candidates aimed at Parkinson's disease, epilepsy, and long-acting pain relief.
Lead candidate with a clearly stated target indication: SER 252 is described as a POZ conjugate for the treatment of Parkinson's disease.
Platform approach extends beyond one therapeutic area: In addition to neurological drug candidates, Serina develops POZ technology in lipid nanoparticle delivered RNA vaccines for infectious diseases.

Bear case

Clinical and regulatory execution risk: With investigational candidates (including SER 252, SER 227, SER 214, and SER 228), outcomes depend on the ability to demonstrate safety and effectiveness with regulators.
Program dependency: The investment case can be concentrated if progress in one or a small number of candidates drives perceived value.
Technology transfer and delivery risks: The company relies on specific technology components (POZ conjugates and lipid nanoparticle delivered RNA), which must perform as intended across programs.

Valuation — source: SEC EDGAR (first-party)
Price	$2.86
Market Cap	$72.65M
Price / Book	3.88
Price / Sales	558.81
FCF Yield	-44.7%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$130000.00
Net Margin	-14755.4%
Revenue Growth (YoY)	132.1%
EPS Growth (YoY)	26.5%
FCF Growth (YoY)	5.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	-20.72 (distress)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.0

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Sio Capital Management, LLC ($1.94M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Steven A. Ledger
Employees	12
Country	US
IPO Date	2000-01-21

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.